ATXI — Avenue Therapeutics Share Price
0.000.00%
Last trade - 00:00- $5.75m
- $3.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.64 | ||
| Price to Tang. Book | 3.64 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2223.24% | ||
| Return on Equity | -378.24% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.
Directors
- Lindsay Rosenwald CHM (66)
- Lucy Lu PRE (46)
- Jaideep Gogtay DRC (54)
- Garrett Ingram DRC (55)
- Curtis Oltmans DRC (57)
- Neil Herskowitz IND (64)
- Jay Kranzler IND (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 9th, 2015
- Public Since
- June 27th, 2017
- No. of Shareholders
- 32
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 44,260,667
- Address
- 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS, 33154
- Web
- https://avenuetx.com/
- Phone
- +1 7816524500
- Contact
- Jaclyn Jaffe
- Auditors
- KPMG LLP
Upcoming Events for ATXI
Avenue Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Avenue Therapeutics Inc Earnings Release
Similar to ATXI
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Avenue Therapeutics share price?
As of Today at 19:03 UTC, shares in Avenue Therapeutics are trading at $0.13. This share price information is delayed by 15 minutes.
How has the Avenue Therapeutics share price performed this year?
Shares in Avenue Therapeutics last closed at $0.13 and the price had moved by -87.5% over the past 365 days. In terms of relative price strength the Avenue Therapeutics share price has underperformed the S&P500 Index by -89.6% over the past year.
What are the analyst and broker recommendations for Avenue Therapeutics?
The overall consensus recommendation for Avenue Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Avenue Therapeutics dividend yield?
Avenue Therapeutics does not currently pay a dividend.
Does Avenue Therapeutics pay a dividend?
Avenue Therapeutics does not currently pay a dividend.
When does Avenue Therapeutics next pay dividends?
Avenue Therapeutics does not currently pay a dividend.
How do I buy Avenue Therapeutics shares?
To buy shares in Avenue Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Avenue Therapeutics?
As of the previous close price of $0.13, shares in Avenue Therapeutics had a market capitalisation of $5.75m.
Where are Avenue Therapeutics shares listed?
Here are the trading details for Avenue Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ATXI
What kind of share is Avenue Therapeutics?
Based on an overall assessment of its quality, value and momentum Avenue Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Avenue Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Avenue Therapeutics is $0.75. That is 476.92% above the last closing price of $0.13.
Analysts covering Avenue Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.41 for the next financial year.
What is the trend in the Avenue Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avenue Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -81.6%.
As of the last closing price of $0.13, shares in Avenue Therapeutics were trading -70.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Avenue Therapeutics PE Ratio?
The Avenue Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Avenue Therapeutics?
Avenue Therapeutics' management team is headed by:
- Lindsay Rosenwald - CHM
- Lucy Lu - PRE
- Jaideep Gogtay - DRC
- Garrett Ingram - DRC
- Curtis Oltmans - DRC
- Neil Herskowitz - IND
- Jay Kranzler - IND